LICENSE CATEGORIES
AVAILABLE LICENSES
LICENSE INFORMATION

Novel Peptide Suppress Cava28 Subnit Function to Reduce Inflammatory and Neuropathic Pain

Tech ID #: 1128.2 CONNECT WITH A MANAGER FOR LICENSING

The global market for pain management is more than $7 billion annually, representing a huge opportunity for products which displace the use of opioids as a first line of treatment.

Description of Technology

The ancillary Cavα2δ subunits contribute to the trafficking and cell surface retention of Cav2 calcium channels. Upregulation of the Cavα2δ-1 subunit in dorsal root ganglion (DRG) neurons is observed after nerve injury and results in an increased synaptic abundance of HVA Cav channels in the spinal dorsal horn, thus enhancing the transmission of pain signals. Blocking function of Cavα2δ is an important pain management mechanism.

A previously recognized endogenous ligand of the Cavα2δ subunit has been identified.

Areas of Application
Therapeutic neuropathic pain management
IP Status
  • Patent Pending
Competitive Advantages
  • A previously unrecognized endogenous ligand of the Cavα2δ subunit has been identified.
  • In vivo expression of the ligand via intrathecal viral delivery potently inhibits inflammatory and neuropathic pain in mice. This potent endogenous ligand of Cavα2δ subunits can potentially be exploited for the management of chronic pain without the side effects that are commonly associated with gabapentinoid drugs.
Stage Of Development
  • In vivo test on mice